UnitedHealthcare (UHC), the United States’ largest private health insurer notifies Aerocrine of their revised coverage decision on FeNO.

UnitedHealthcare (UHC), the United States’ largest private health insurer
notifies Aerocrine of their revised coverage decision on FeNO.

SOLNA, Sweden - 12 March, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO)
announces that United Healthcare has retired its negative coverage policy
effective April 1, 2012.

Aerocrine received notification late afternoon on Friday, March 9, 2012 of UHC’s
decision to retire their negative coverage policy regarding Fractional exhaled
Nitric Oxide (FeNO). UHC provides insurance coverage for approximately 15% of
all privately insured lives in the United States or approximately 26 million
lives. UHC subsidiaries include Oxford Health, PacifiCare, MAMSI, Sierra Life
and Golden Rule Insurance companies. UHC operates in all 50 states and the
District of Columbia. They also administer benefits coverage for several million
public insurer lives which includes portions of Medicare and Medicaid.

With this and other recent coverage changes, the number of insured lives that
are eligible for reimbursement for Aerocrine’s test continues to increase. Based
on positive coverage decisions as well as negative policies being retired,
Aerocrine estimates that this represents over 35% of privately insured lives
thereby increasing from about 15% at the end of 2011.1

“The momentum for change in coverage policies since the publication of the ATS
Guideline on FeNO last September continues to grow as several major insurance
companies have undertaken a review of their FeNO coverage policy”, said Scott
Myers, CEO, Aerocrine. “We believe the positive change at UHC will improve
clinical practice and health economic outcomes for asthma management.”

Asthma is one of this world’s most common and costly diseases, affecting 8-10%
of the population and costing over $50B annually in the US alone. The disease
has no cure and proper diagnosis and management of the disease are key to
physicians effectively treating patients.
Aeorcrine’s NIOX MINO monitor and tests are sold to physicians to help them
diagnose airway inflammation, the underlying cause of the majority of asthmatic
conditions. FeNO testing can also help physicians identify patients who will be
responsive to treatment with anti-inflammatory medications such as inhaled
corticosteroids (ICS), and alert them to patients who are not adhering to their
treatments.

“This test allows the presence of steroid responsive airway inflammation to be
identified and also to help ensure that the correct types of medication are
given to the patient at the appropriate time – this is truly personalized
medicine. By gaining improved reimbursement, this will create the paradigm shift
in improving diagnosis and treatment of asthma”, said Dr. Neal Jain, MD, FAAAAI,
FAAP.

“When we received word from UHC of this positive change, we were very happy for
our physicians and patients that were awaiting improved reimbursement. We have
also been informed that UHC has notified many doctors directly by email of the
policy change so this information is getting out. Our field force will be out
discussing this positive change starting today.” said Kathy Hodgdon, US Director
of Sales and Marketing, Aerocrine.

For more information regarding the change in the UHC policy see the following
link:

www.unitedhealthcareonline.com

1)     AIS 2011 Directory of Health Plans, Health Plans USA 2011, www.CMS.gov

For more information, contact:

Scott Myers, President & CEO, Aerocrine AB, Phone: +46 768 788 379

Kathy Hodgdon, Director of Sales & Marketing, Aerocrine Inc., telephone +1 (314)
566 8546

Chip Neff, President, Aerocrine Inc., telephone +1 (919) 696 4267